country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P84060

Copy Link Print Information

FGFR1 Antibody (YA3757)

Name: FGFR1 Antibody (YA3757)
Brand: MedChemExpress
SKU: HY-P84060
Price: 96.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: CEK; FLG; OGD; FLT2; KAL2; BFGFR; CD331; FGFBR; HBGFR)

Avis client

Based on 1 Customer Validation

FGFR1 Antibody (YA3757) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to FGFR1.

For research use only. We do not sell to patients.

Host:
Mouse
Isotype:
IgG
Application:
FC, ELISA
Reactivity :
Human, Mouse

Formulation:
Supplied in ascitic fluid containing 0.03% sodium azide.

Conjugation:
Non-conjugated

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Applications
Product Details
Product Properties
- Appearance
- Formulation
- Concentration
- Storage & Stability
- Livraison
Background
Documentation
References
Help & FAQs
Classifications
Bioz

Applications

Application	FC FC: Flow Cytometry	ELISA ELISA: Enzyme Linked Immunosorbent Assay
Dilution Ratio	1:200-1:400	1:10000

Product Details

Description

FGFR1 Antibody (YA3757) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to FGFR1.

Host Mouse
Clonality Monoclonal
Species Reactivity
Human, Mouse
Observed Molecular Weight

Observed band size: 140 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Calculated Molecular Weight Predicted band size: 92 kDa

Immunogen

Purified recombinant extracellular fragment of human FGFR1 (aa22-376) fused with hIgGFc tag expressed in HEK293 cells.

Purification

affinity purified.

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

RRID

AB_3718824

Product Properties

Appearance

Solution
Formulation

Supplied in ascitic fluid containing 0.03% sodium azide.
Concentration

Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
Livraison

Shipping with blue ice.

Background

Function

FGFR1 is a cell-surface tyrosine kinase FGF receptor that mediates biological responses after ligand binding with heparin/heparan sulfate as a cofactor^[1]. Mechanistically, FGFR signaling activates downstream MAPK, STAT, PI3K/Akt, PLCγ, DAG-PKC, and IP3-Ca²⁺ branches that regulate proliferation, differentiation, apoptosis, and migration^[2]. In adipocytes, FGFR1c is abundantly expressed in white adipose tissue, where adipocyte FGFR1 supports FGF21-stimulated metabolic transcriptional activity and glucose, insulin, triglyceride, and energy-expenditure responses^[1]^[3]. In neural lineage models, FGF2 activation of FGFR1 inhibits oligodendrocyte progenitor differentiation, while oligodendroglial FGFR1 deletion ameliorates experimental autoimmune encephalomyelitis and reduces myelin and axonal loss^[4]^[5]. Compared with related isoforms, FGFR1/2/3 generate IIIb and IIIc splice variants with distinct ligand-binding specificity, whereas FGFR4 lacks this IIIb/IIIc isoform structure^[1]. For experimental applications, the β-Klotho antibody 39F7 specifically activates β-Klotho/FGFR1c signaling, while PD173074 blocks FGFR1 signaling in TGF-β1-induced epithelial-to-mesenchymal transition models^[6]^[7].
Subcellular Localization

Cell membrane; Single-pass type I membrane protein; Nucleus; Cytoplasm, cytosol; Cytoplasmic vesicle
Expression

Tissue_specificity:This protein was detected in astrocytomas, neuroblastomas, and adrenocortical cell lines. Some subtypes were also detected in foreskin fibroblast cell lines, but subtypes 17, 18, and 19 were not detected in these cells.
Isoforms & Post-Translational Modification

P11362 has 21 isomers: P11362-1: 91868 Da (predicted); P11362-8: 73475 Da (predicted); P11362-17: 6682 Da (predicted); P11362-2: 91668 Da (predicted); P11362-9: 73274 Da (predicted); P11362-3: 82162 Da (predicted); P11362-10: 63769 Da (predicted); P11362-4: 81962 Da (predicted); P11362-11: 63569 Da (predicted); P11362-5: 74133 Da (predicted); P11362-12: 55740 Da (predicted); P11362-6: 73933 Da (predicted); P11362-13: 55540 Da (predicted); P11362-7: 91580 Da (predicted); P11362-14: 81875 Da (predicted); P11362-15: 16487 Da (predicted); P11362-16: 33412 Da (predicted); P11362-18: 33125 Da (predicted); P11362-19: 91760 Da (predicted); P11362-20: 90618 Da (predicted); P11362-21: 95344 Da (predicted).
Autophosphorylated. Binding of FGF family members together with heparan sulfate proteoglycan or heparin promotes receptor dimerization and autophosphorylation on tyrosine residues. Autophosphorylation occurs in trans between the two FGFR molecules present in the dimer and proceeds in a highly ordered manner. Initial autophosphorylation at Tyr-653 increases the kinase activity by a factor of 50 to 100. After this, Tyr-583 becomes phosphorylated, followed by phosphorylation of Tyr-463, Tyr-766, Tyr-583 and Tyr-585. In a third stage, Tyr-654 is autophosphorylated, resulting in a further tenfold increase of kinase activity. Phosphotyrosine residues provide docking sites for interacting proteins and so are crucial for FGFR1 function and its regulation;Ubiquitinated. FGFR1 is rapidly ubiquitinated by NEDD4 after autophosphorylation, leading to internalization and lysosomal degradation. CBL is recruited to activated FGFR1 via FRS2 and GRB2, and mediates ubiquitination and subsequent degradation of FGFR1;N-glycosylated in the endoplasmic reticulum. The N-glycan chains undergo further maturation to an Endo H-resistant form in the Golgi apparatus
Subunit

Monomer. Homodimer after ligand binding. Interacts predominantly with FGF1 and FGF2, but can also interact with FGF3, FGF4, FGF5, FGF6, FGF8, FGF10, FGF19, FGF21, FGF22 and FGF23 (in vitro) (PubMed:12181353, PubMed:16597617, PubMed:1697263, PubMed:1722683, PubMed:17623664, PubMed:8663044, PubMed:9655399). Ligand specificity is determined by tissue-specific expression of isoforms, and differences in the third Ig-like domain are crucial for ligand specificity. Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB increases the affinity for FGF19, FGF21 and FGF23 (PubMed:19966287). Interacts (phosphorylated on Tyr-766) with PLCG1 (via SH2 domains) (PubMed:1379697, PubMed:1656221, PubMed:21765395). Interacts with FRS2 (PubMed:21765395). Interacts with RPS6KA1 (PubMed:15117958). Interacts (via C-terminus) with NEDD4 (via WW3 domain) (PubMed:21765395). Interacts with KL (By similarity). Interacts with SHB (via SH2 domain) (PubMed:12181353). Interacts with GRB10 (PubMed:10454568). Interacts with ANOS1; this interaction does not interfere with FGF2-binding to FGFR1, but prevents binding of heparin-bound FGF2 (PubMed:19696444). Interacts with SOX2 and SOX3. Interacts with FLRT1, FLRT2 and FLRT3 (By similarity). Found in a ternary complex with FGF1 and ITGAV:ITGB3 (PubMed:18441324, PubMed:20422052)
SwissProt ID

P11362
Gene ID

2260 [NCBI]
Synonyms

CEK; FLG; OGD; FLT2; KAL2; BFGFR; CD331; FGFBR; HBGFR

Documentation

Select Batch:

Fiche technique (262 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
User Guide for Antibodies (1077 KB)

References

[1]. Ohta H, et al. Fgf signaling in adipocytes as a target for metabolic diseases. Mol Metab. 2012 Dec 14;2(1):3-4. [Content Brief]

[2]. de Menezes D L, et al. 577 POSTER TKl258 is an effective multitargeted receptor tyrosine kinase (RTK) inhibitor against prostate cancer models via potent inhibition of FGFR kinase[J]. European Journal of Cancer Supplements, 2006, 4(12): 175.

[3]. Lee S, et al. Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling. Nature. 2018 Jan 25;553(7689):501-505. [Content Brief]

[4]. Zhou YX, et al. Retroviral lineage analysis of fibroblast growth factor receptor signaling in FGF2 inhibition of oligodendrocyte progenitor differentiation. Glia. 2006 Nov 1;54(6):578-90. [Content Brief]

[5]. Rajendran R, et al. Oligodendroglial fibroblast growth factor receptor 1 gene targeting protects mice from experimental autoimmune encephalomyelitis through ERK/AKT phosphorylation. Brain Pathol. 2018 Mar;28(2):212-224. [Content Brief]

[6]. Min X, et al. Agonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions. J Biol Chem. 2018 Sep 21;293(38):14678-14688. [Content Brief]

[7]. Životić M, et al. Modulation of NCAM/FGFR1 signaling suppresses EMT program in human proximal tubular epithelial cells. PLoS One. 2018 Nov 1;13(11):e0206786. [Content Brief]